

# Ute Hegenbart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8099243/publications.pdf>

Version: 2024-02-01

245  
papers

10,871  
citations

44444

50  
h-index

38517

99  
g-index

251  
all docs

251  
docs citations

251  
times ranked

8300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of AL proteins from 10 $\lambda$ -AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 27-37.	1.4	4
2	Response to extracorporeal photopheresis therapy of patients with steroid-refractory/resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. <i>Cytotherapy</i> , 2022, 24, 311-319.	0.3	7
3	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 1-7.	1.4	42
4	Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement. <i>PLoS ONE</i> , 2022, 17, e0264407.	1.1	10
5	Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation. <i>Vaccines</i> , 2022, 10, 330.	2.1	9
6	Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. <i>HemaSphere</i> , 2022, 6, e688.	1.2	1
7	Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 245-254.	1.4	5
8	Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. <i>Annals of Hematology</i> , 2021, 100, 2087-2093.	0.8	29
9	The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 30-37.	1.3	5
10	Targeting transthyretin —Mechanism—based treatment approaches and future perspectives in hereditary amyloidosis. <i>Journal of Neurochemistry</i> , 2021, 156, 802-818.	2.1	16
11	Solid state NMR assignments of a human $\lambda$ -III immunoglobulin light chain amyloid fibril. <i>Biomolecular NMR Assignments</i> , 2021, 15, 9-16.	0.4	8
12	Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 91-99.	1.4	8
13	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 1-2.	1.4	49
14	Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis. <i>Clinical Research in Cardiology</i> , 2021, 110, 579-590.	1.5	3
15	Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. <i>Nature Communications</i> , 2021, 12, 875.	5.8	70
16	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. <i>World Journal of Cardiology</i> , 2021, 13, 55-67.	0.5	2
17	Elevated interleukin-6 levels are associated with impaired outcome in cardiac transthyretin amyloidosis. <i>World Journal of Cardiology</i> , 2021, 13, 55-67.	0.5	1
18	Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD). <i>Leukemia and Lymphoma</i> , 2021, 62, 2267-2271.	0.6	0

#	ARTICLE	IF	CITATIONS
19	<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>lightâ€chain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology, 2021, 96, E253-E257.	2.0	13
20	Search for AL amyloidosis risk factors using Mendelian randomization. Blood Advances, 2021, 5, 2725-2731.	2.5	5
21	Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. European Journal of Haematology, 2021, 107, 449-457.	1.1	13
22	Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Annals of Hematology, 2021, 100, 2387-2398.	0.8	11
23	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. British Journal of Haematology, 2021, 195, 230-243.	1.2	11
24	Submyeloablative total body irradiationâ€based conditioning and allogeneic stem cell transplantation in highâ€risk myeloma with early progression after upâ€front autologous transplantation. British Journal of Haematology, 2021, , .	1.2	1
25	Protease resistance of <i>ex vivo</i> amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 243-251.	1.4	25
26	Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13473.	1.7	6
27	Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nature Communications, 2021, 12, 6434.	5.8	36
28	OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S23-S24.	0.2	0
29	Easix before Conditioning Therapy Predicts Sepsis after Allogeneic Stem Cell Transplantation. Blood, 2021, 138, 1774-1774.	0.6	0
30	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	0.6	4
31	Multi-Modality Imaging Reveals Structural Centrosome Aberrations As a Potential Driver of Chromosomal Instability in Early-Stage Plasma Cell Disorders. Blood, 2021, 138, 1579-1579.	0.6	0
32	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	0.6	6
33	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	0.6	5
34	Th22 and Tfh Cell Elevation Is Associated with Clinical Response of Photopheresis Therapy in Patients with Steroid-Refractory/ Resistant Graft-Versus-Host Disease (GvHD). Blood, 2021, 138, 1810-1810.	0.6	0
35	Two-Year Evaluation of the German Clinical Amyloidosis Registry. Blood, 2021, 138, 3780-3780.	0.6	3
36	P-175: Outcomes of autologous-allogeneic vs autologous tandem approach followed by thalidomide maintenance for transplant-eligible patients with newly diagnosed multiple myeloma: a prospective phase II-study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S132.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Treatment in AL Amyloidosis: Moving towards Individualized and Clone-Directed Therapy. <i>Hemato</i> , 2021, 2, 739-747.	0.2	1
38	A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2020, 109, 700-713.	1.5	13
39	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. <i>Leukemia</i> , 2020, 34, 1187-1191.	3.3	13
40	Seeded fibrils of the germline variant of human $\lambda$ -III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability. <i>Journal of Biological Chemistry</i> , 2020, 295, 18474-18484.	1.6	15
41	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. <i>Blood Advances</i> , 2020, 4, 6157-6168.	2.5	26
42	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <i>Blood</i> , 2020, 135, 1517-1530.	0.6	67
43	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
44	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 231-236.	1.4	20
45	Prognosis and Staging of AL Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 388-400.	0.7	34
46	CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort. <i>European Journal of Radiology</i> , 2020, 129, 109123.	1.2	9
47	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	2.0	25
48	High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. <i>Annals of Hematology</i> , 2020, 99, 855-866.	0.8	6
49	Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 799-807.	1.7	20
50	Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation. <i>ELife</i> , 2020, 9, .	2.8	33
51	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
52	Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
53	Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 53.	1.6	25
54	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	1.7	29

#	ARTICLE	IF	CITATIONS
55	Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. <i>Haematologica</i> , 2019, 104, e304-e306.	1.7	9
56	AL amyloidosis with a localized B cell neoplasia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 353-363.	1.4	15
57	New sequence variants in patients affected by amyloidosis show transthyretin instability by isoelectric focusing. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 85-93.	1.4	6
58	Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. <i>Nature Communications</i> , 2019, 10, 1103.	5.8	120
59	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27
60	Shaping of CD56 <sup>+</sup> Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. <i>Frontiers in Immunology</i> , 2019, 10, 547.	2.2	16
61	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. <i>Clinical Research in Cardiology</i> , 2019, 108, 1324-1330.	1.5	93
62	The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis. <i>Blood</i> , 2019, 134, 3328-3328.	0.6	1
63	High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia. <i>Blood</i> , 2019, 134, 3077-3077.	0.6	0
64	Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies. <i>Blood</i> , 2019, 134, 1358-1358.	0.6	0
65	A Semi-Automated Knife-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations. <i>Blood</i> , 2019, 134, 3379-3379.	0.6	0
66	Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2019, 134, 3287-3287.	0.6	0
67	Obesity is a significant susceptibility factor for idiopathic AA amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 37-45.	1.4	24
68	Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 611-618.	0.3	66
69	Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 767-776.	0.7	13
70	Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e161-e169.	2.2	67
71	The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2018, 97, 1241-1250.	0.8	31
72	Cerebral amyloidoma is characterized by clonal cell clonality and a stable clinical course. <i>Brain Pathology</i> , 2018, 28, 234-239.	2.1	14

#	ARTICLE	IF	CITATIONS
73	Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. <i>Hematological Oncology</i> , 2018, 36, 210-216.	0.8	14
74	First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. <i>Blood</i> , 2018, 131, 368-371.	0.6	30
75	Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 68-69.	1.4	0
76	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2018, 103, 336-343.	1.7	18
77	Deferred autologous stem cell transplantation in systemic AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 101.	2.8	28
78	Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2207.	2.2	21
79	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	2.5	33
80	<sc>CD</sc>7 is expressed on a subset of normal <sc>CD</sc>34<sup>+</sup> positive myeloid precursors. <i>European Journal of Haematology</i> , 2018, 101, 318-325.	1.1	6
81	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
82	MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. <i>Neurology</i> , 2018, 91, e625-e634.	1.5	24
83	Local vs. systemic pulmonary amyloidosisâ€™ impact on diagnostics and clinical management. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 627-637.	1.4	31
84	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. <i>Blood</i> , 2018, 132, 1988-1991.	0.6	30
85	CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myelomaâ€™ Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. <i>Frontiers in Immunology</i> , 2018, 9, 1676.	2.2	32
86	AL Amyloidosis â€™ Pathogenesis and Prognosis Are Determined By the Amyloidogenic Potential of the Light Chain and the Molecular Characteristics of Malignant Plasma Cells. <i>Blood</i> , 2018, 132, 187-187.	0.6	5
87	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidosis: A European Retrospective Series of 150 Patients. <i>Blood</i> , 2018, 132, 3264-3264.	0.6	0
88	No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy. <i>Blood</i> , 2018, 132, 3399-3399.	0.6	1
89	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 145-152.	0.7	13
90	Amyloid in bone marrow smears in systemic light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 52-59.	1.4	18

#	ARTICLE	IF	CITATIONS
91	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 56-57.	1.4	9
92	Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images—reference values and performance in patients with heart failure and left ventricular hypertrophy. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1414-1422.	0.5	32
93	Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. <i>Haematologica</i> , 2017, 102, 1424-1431.	1.7	39
94	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 7510-7514.	7.2	59
95	AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. <i>Blood</i> , 2017, 130, 632-642.	0.6	104
96	Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. <i>Angewandte Chemie</i> , 2017, 129, 7618-7622.	1.6	10
97	Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. <i>Haematologica</i> , 2017, 102, 1281-1290.	1.7	15
98	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSC CLL3X trial. <i>British Journal of Haematology</i> , 2017, 179, 342-346.	1.2	2
99	Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate. <i>Journal of Biological Chemistry</i> , 2017, 292, 2328-2344.	1.6	37
100	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSC CLL3X trial. <i>Blood</i> , 2017, 130, 1477-1480.	0.6	63
101	Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1870-1878.	2.0	9
102	Flow in a fibril-forming disease. <i>Blood</i> , 2017, 129, 7-8.	0.6	2
103	Sural nerve injury in familial amyloid polyneuropathy. <i>Neurology</i> , 2017, 89, 475-484.	1.5	48
104	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. <i>Haematologica</i> , 2017, 102, e411-e414.	1.7	7
105	Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e119-e120.	0.2	1
106	Polymorphism of Amyloid Fibrils In Vivo. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 4822-4825.	7.2	109
107	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. <i>Blood</i> , 2016, 128, 594-602.	0.6	67
108	Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis. <i>Cancer Medicine</i> , 2016, 5, 1464-1472.	1.3	25

#	ARTICLE	IF	CITATIONS
109	Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 1188-1196.	1.2	11
110	Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 569-577.	1.4	93
111	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. <i>Blood</i> , 2016, 128, 1066-1066.	0.6	5
112	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed AL Amyloidosis. <i>Blood</i> , 2016, 128, 4628-4628.	0.6	1
113	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gclsg CLL3X Trial. <i>Blood</i> , 2016, 128, 682-682.	0.6	3
114	Hematopoietic stem cell transplantation (HSCT) compared to consolidation chemotherapy (CT) to increase leukemia free survival (LFS) in acute myelogenous leukemia (AML) patients between 60 and 75 years irrespective of genetic risk: Report from the AML 2004 of the East German Study Group (OSHO).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18501-e18501.	0.8	6
115	Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice: a Single Center Experience. <i>Blood</i> , 2016, 128, 5686-5686.	0.6	0
116	Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. <i>Transplantation</i> , 2015, 99, 1065-1071.	0.5	24
117	Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 45-53.	1.4	15
118	Risk factors for AA amyloidosis in Germany. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 1-7.	1.4	24
119	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. <i>Journal of Clinical Oncology</i> , 2015, 33, 1371-1378.	0.8	185
120	In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. <i>Brain</i> , 2015, 138, 549-562.	3.7	112
121	Clinical and Cytogenetic Characterization of Light Chain Amyloidosis Patients with a Low Amyloidogenic Free Light Chain Count at First Diagnosis. <i>Blood</i> , 2015, 126, 1790-1790.	0.6	2
122	ATG and Statins Reduce Incidence of Severe Chronic Gvhd By Distinct Mechanisms Involving CXCL9 and Kynurenine Catabolism. <i>Blood</i> , 2015, 126, 856-856.	0.6	1
123	Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 35095-35106.	0.8	12
124	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	0.6	0
125	Very Good Response and Overall Survival after Allogeneic Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis; Results of a Non-Interventional Study By the Plasma Cell Disorder Subcommittee of the Chronic Malignancy Working Party of the EBMT. <i>Blood</i> , 2015, 126, 4397-4397.	0.6	0
126	Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2008-2008.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Cytokeratin (CK)-18 and CK18 Fragments As Sensitive and Specific Biomarkers of Acute Hepato-Intestinal Gvhd: Results of a Prospective Observational Study. <i>Blood</i> , 2015, 126, 3083-3083.	0.6	1
128	Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies. <i>Blood</i> , 2015, 126, 2517-2517.	0.6	0
129	Imatinib-supplemented myeloablative total-body irradiation/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia. <i>European Journal of Haematology</i> , 2014, 92, 546-549.	1.1	1
130	Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. <i>International Journal of Cardiology</i> , 2014, 176, 1113-1115.	0.8	6
131	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 9-17.	1.4	84
132	High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy. <i>Haematologica</i> , 2014, 99, 541-547.	1.7	19
133	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 123, 2960-2967.	0.6	62
134	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. <i>Blood</i> , 2014, 124, 2325-2332.	0.6	366
135	Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry. <i>Blood</i> , 2014, 124, 2068-2068.	0.6	3
136	Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO). <i>Blood</i> , 2014, 124, 280-280.	0.6	8
137	Telomere Length and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSC CLL3X Trial. <i>Blood</i> , 2014, 124, 1951-1951.	0.6	0
138	Serum Asymmetric Dimethylarginine (ADMA) Levels Predict Steroid-Refractory Gvhd before Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3908-3908.	0.6	0
139	Pre-Transplant Weight Loss Influences Outcome of Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3950-3950.	0.6	0
140	Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3666-3666.	0.6	1
141	Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1181-1181.	0.6	0
142	Extended Resection of a Plasmocytoma of Bone and an Amyloidoma of the Chest Wall. <i>Annals of Thoracic Surgery</i> , 2013, 96, 2223-2225.	0.7	6
143	Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 22-27.	2.0	113
144	Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. <i>International Journal of Cardiology</i> , 2013, 164, 179-184.	0.8	37

#	ARTICLE	IF	CITATIONS
145	Doxycycline in ATTRY69H (p.ATTRY89H) amyloidosis with predominant leptomeningeal manifestation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 279-280.	1.4	4
146	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013, 121, 5055-5063.	0.6	171
147	TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood, 2013, 121, 3284-3288.	0.6	96
148	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	0.6	385
149	Prognostic Factors For Overall Survival In Elderly Patients With Relapsed Acute Myeloid Leukemia " Retrospective Study On Behalf Of The East German Study Group For Hematology and Oncology (OSHO). Blood, 2013, 122, 1409-1409.	0.6	0
150	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 303-303.	0.6	0
151	Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3314-3314.	0.6	0
152	Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years. Blood, 2013, 122, 2645-2645.	0.6	1
153	Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex). Blood, 2013, 122, 1993-1993.	0.6	1
154	Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis. Blood, 2013, 122, 417-417.	0.6	1
155	Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood, 2012, 119, 488-493.	0.6	200
156	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	0.8	735
157	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 1035-1044.	5.1	237
158	Longitudinal Left Ventricular Function for Prediction of Survival in Systemic Light-Chain Amyloidosis. Journal of the American College of Cardiology, 2012, 60, 1067-1076.	1.2	253
159	Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects. Annals of Hematology, 2012, 91, 1129-1133.	0.8	11
160	Treatment of AL Amyloidosis with Bendamustine. Blood, 2012, 120, 4057-4057.	0.6	5
161	SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 2012, 120, 966-966.	0.6	1
162	Factors Influencing Complete Remission (CR) Rate in Patients " 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study. Blood, 2012, 120, 128-128.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning Intensity. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1250-1254.	2.0	80
164	Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). <i>Blood</i> , 2011, 117, 3809-3815.	0.6	60
165	Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. <i>Blood</i> , 2011, 118, 1685-1692.	0.6	182
166	Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma. <i>Journal of Immunology</i> , 2011, 187, 1047-1056.	0.4	33
167	An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Blood</i> , 2011, 118, 157-157.	0.6	1
168	Impact of Bendamustine Pretreatment on Stem Cell Mobilization and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 1933-1933.	0.6	5
169	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	0.6	5
170	Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,. <i>Blood</i> , 2011, 118, 3946-3946.	0.6	0
171	Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,. <i>Blood</i> , 2011, 118, 4124-4124.	0.6	0
172	Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. <i>Blood</i> , 2010, 116, 522-528.	0.6	84
173	Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. <i>Blood</i> , 2010, 116, 2455-2461.	0.6	109
174	Amyloid in endomyocardial biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 523-532.	1.4	50
175	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. <i>Blood</i> , 2010, 116, 1364-1364.	0.6	19
176	Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III). <i>Blood</i> , 2010, 116, 1960-1960.	0.6	1
177	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. <i>Blood</i> , 2010, 116, 2357-2357.	0.6	3
178	Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2376-2376.	0.6	2
179	Successful Mobilization of Peripheral Blood Stem Cells After Intensive Bendamustine Pre-Treatment In Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 4439-4439.	0.6	10
180	Pentostatin for First-Line Salvage Therapy of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease; a Dual Center Retrospective Analysis. <i>Blood</i> , 2010, 116, 1274-1274.	0.6	0

#	ARTICLE	IF	CITATIONS
181	The Impact of Donor Type In Patients with AML and High Risk Cytogenetic Aberrations. <i>Blood</i> , 2010, 116, 2369-2369.	0.6	0
182	Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2748-2748.	0.6	0
183	Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation. <i>Haematologica</i> , 2009, 94, 594-596.	1.7	3
184	Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". <i>Haematologica</i> , 2009, 94, 439-441.	1.7	5
185	Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light chain amyloidosis. <i>European Journal of Heart Failure</i> , 2009, 11, 1014-1020.	2.9	45
186	Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. <i>Annals of Hematology</i> , 2009, 88, 67-71.	0.8	53
187	Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 257-262.	1.2	116
188	Prevalence of Germline Mutations in the TTR Gene in a Consecutive Series of Surgical Pathology Specimens With ATTR Amyloid. <i>American Journal of Surgical Pathology</i> , 2009, 33, 58-65.	2.1	39
189	Prospective Phase II Study Using Dexamethasone Induction Therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem Cell Transplantation in 30 Patients with Systemic AL Amyloidosis.. <i>Blood</i> , 2009, 114, 3401-3401.	0.6	1
190	Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.. <i>Blood</i> , 2009, 114, 52-52.	0.6	15
191	Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.. <i>Blood</i> , 2009, 114, 2823-2823.	0.6	1
192	Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 3400-3400.	0.6	0
193	Three German fibrinogen A $\alpha$ -chain amyloidosis patients with the p.Glu526Val mutation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 25-31.	1.4	21
194	Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. <i>Heart Rhythm</i> , 2008, 5, 235-240.	0.3	214
195	Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5183-5191.	0.8	139
196	Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 129-136.	1.4	1
197	Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. <i>Haematologica</i> , 2008, 93, 459-462.	1.7	62
198	Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. <i>Blood</i> , 2008, 111, 4700-4705.	0.6	103

#	ARTICLE	IF	CITATIONS
199	Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. <i>Haematologica</i> , 2008, 93, 955-956.	1.7	14
200	Single Center Experience of Lenalidomide/Dexamethasone Treatment in 40 Patients with Light Chain Amyloidosis: High Toxicity in Patients with Severe Impaired Renal and Cardiac Function.. <i>Blood</i> , 2008, 112, 1736-1736.	0.6	5
201	Improvement of Long-Term Survival after High-Dose Melphalan in Patients with Light Chain Amyloidosis Responding to Induction Chemotherapy.. <i>Blood</i> , 2008, 112, 3334-3334.	0.6	6
202	Evaluation of Safety and Efficacy of Different Stem Cell Mobilization Regimens in 110 Patients with Light Chain Amyloidosis. <i>Blood</i> , 2008, 112, 3709-3709.	0.6	3
203	Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSC CLL3X study). <i>Blood</i> , 2008, 112, 565-565.	0.6	6
204	Non-invasive predictors of survival in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2007, 9, 617-624.	2.9	109
205	MR-Relaxometry of Myocardial Tissue. <i>Investigative Radiology</i> , 2007, 42, 636-642.	3.5	57
206	Rapid Progression of Left Ventricular Wall Thickness Predicts Mortality in Cardiac Light-chain Amyloidosis. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1313-1319.	0.3	52
207	Effect of CD34+cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2007, 78, 21-28.	1.1	58
208	Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients.. <i>Blood</i> , 2007, 110, 172-172.	0.6	1
209	Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.. <i>Blood</i> , 2007, 110, 2500-2500.	0.6	1
210	Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.. <i>Blood</i> , 2007, 110, 1651-1651.	0.6	0
211	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2006, 24, 444-453.	0.8	243
212	Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. <i>Blood</i> , 2006, 107, 2578-2584.	0.6	62
213	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. <i>Blood</i> , 2006, 107, 3415-3416.	0.6	75
214	Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3018-3018.	0.6	0
215	Serum Cytokeratin-18 Fragments as Quantitative Marker of Epithelial Apoptosis in Liver and Intestinal Graft-Versus-Host Disease.. <i>Blood</i> , 2006, 108, 3234-3234.	0.6	0
216	Treatment of High Risk AML and MDS with Ara-C-Containing Standard Chemotherapy Followed by Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC-SCT) during Aplasia: A Survey of the German Cooperative Transplant Study Group (GCTSG).. <i>Blood</i> , 2006, 108, 5376-5376.	0.6	0

#	ARTICLE	IF	CITATIONS
217	The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. <i>Haematologica</i> , 2006, 91, 1555-8.	1.7	36
218	Indications for Liver Transplantation in Patients with Amyloidosis: A Single-Center Experience with 11 Cases. <i>Transplantation</i> , 2005, 80, S156-S159.	0.5	16
219	Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis. <i>Transplantation</i> , 2005, 80, S160-S163.	0.5	18
220	Risk Stratification in Cardiac Amyloidosis: Novel Approaches. <i>Transplantation</i> , 2005, 80, S151-S155.	0.5	23
221	Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 275-281.	2.0	14
222	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 129, 381-391.	1.2	41
223	Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3819-3829.	0.8	214
224	Higher Interleukin-10 (IL-10) and Lower Interferon-Gamma (IFN- $\gamma$ ), Tumor Necrosis Factor Alpha (TNF- $\alpha$ ), IL-6, IL-8 Serum Levels in Patients Undergoing Reduced Intensity Versus Conventional Intensity Conditioning Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2005, 106, 5208-5208.	0.6	0
225	Cytogenetics and De Novo/Secondary AML but Not Age Are the Main Determinants for CR Rate and Hematological Recovery in Acute Myeloid Leukemia (AML) Using Intermediate Doses of Cytarabine (AraC) Delivered at the Presumptive Saturating Infusion Rate.. <i>Blood</i> , 2005, 106, 1851-1851.	0.6	2
226	Treatment of Myeloid and Lymphoid Malignancies with Highly Purified Alloreactive CD56+CD3 $\alpha^+$ NK-Cells and Haploidentical Stem Cell Transplantation: Promising Results of a Phase I Study.. <i>Blood</i> , 2005, 106, 2906-2906.	0.6	0
227	High-Dose Melphalan Chemotherapy with Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: No Increased Mortality Using Induction and Mobilization Chemotherapy.. <i>Blood</i> , 2005, 106, 5505-5505.	0.6	0
228	Remission Induction Using Alemtuzumab can Permit Chemotherapy-refractory Chronic Lymphocytic Leukemia (CLL) Patients to Undergo Allogeneic Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 2455-2458.	0.6	6
229	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Blood</i> , 2004, 103, 790-795.	0.6	124
230	Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2004, 104, 2759-2759.	0.6	2
231	Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. <i>Blood</i> , 2004, 104, 3074-3074.	0.6	2
232	Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 2323-2323.	0.6	4
233	Outcome of Patients with Primary Mediastinal Large B-Cell Non-Hodgkin's Lymphomas: A Single Institution Analysis from 1996-2004.. <i>Blood</i> , 2004, 104, 3302-3302.	0.6	0
234	Recovery of Polyclonal Immunoglobulin Synthesis after Autologous Stem Cell Transplantation in Multiple Myeloma Patients as a Prognostic Factor for Event-Free Survival.. <i>Blood</i> , 2004, 104, 939-939.	0.6	0

#	ARTICLE	IF	CITATIONS
235	High CD34+ Cell Dose Is a Significant Factor for Hematologic Reconstitution of Patients with Multiple Myeloma (MM) or AL-Amyloidosis Undergoing Autologous Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 1157-1157.	0.6	0
236	Prognostic Relevance of "Early-Onset" Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004, 104, 423-423.	0.6	0
237	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003, 120, 281-288.	1.2	90
238	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 266-272.	2.0	31
239	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i> , 2003, 101, 1620-1629.	0.6	424
240	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	0.6	382
241	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. <i>Blood</i> , 2003, 102, 2021-2030.	0.6	320
242	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
243	Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. <i>International Journal of Antimicrobial Agents</i> , 2000, 15, 119-123.	1.1	25
244	Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999, 104, 382-391.	1.2	40
245	Sequential high-dose treatment with peripheral blood progenitor cell transplantation in patients with multiple myeloma. <i>Stem Cells</i> , 1995, 13, 36-41.	1.4	4